首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1629867

全球人工智慧驱动的医疗设备市场 - 2025-2033

Global AI-Powered Medical Devices Market - 2025-2033

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球人工智慧医疗设备市场规模达257亿美元，预计2033年将达到848亿美元，2025-2033年预测期间复合年增长率为12.9%。

人工智慧驱动的医疗设备利用机器学习、深度学习和自然语言处理等人工智慧技术来改善医疗诊断、治疗和患者监测，正在彻底改变医疗保健领域。这些设备分析大量资料，提供即时见解，并自动执行复杂的任务，从而提高效率和患者治疗效果。从先进的影像系统到用于持续健康监测的可穿戴设备，人工智慧驱动的医疗设备正在重塑个人化和预防性护理，优化医院工作流程，推动医学新时代，实现更快的决策和更有效的治疗策略。

市场动态：

驱动程式和限制

对个人化和精准医疗的需求不断增长

全球人工智慧驱动的医疗设备市场是由对个人化和精准医疗不断增长的需求所推动的，这正在彻底改变病患照护。人工智慧技术的进步使医疗保健提供者能够分析大量资料集，包括遗传资讯、病史、生活方式因素和即时健康指标，以提供高度客製化的治疗计划。整合到穿戴式医疗设备中的人工智慧演算法可以持续监测患者的健康参数，在潜在问题变得严重之前提醒临床医生，并提高诊断影像的诊断准确性。这些功能不仅可以提高患者的治疗效果，还可以透过减少不必要的检查和住院来优化资源分配。

随着全球慢性病和人口老化的加剧，精准和主动照护的需求变得越来越重要。北美和欧洲等地区的医疗保健政策和激励措施鼓励采用人工智慧驱动的解决方案。随着精准医疗的普及，人工智慧医疗设备与日常医疗保健实践的整合预计将加速，从而显着推动市场扩张。

例如，2024年5月，OM1推出了三款新产品：OM1 Orion、OM1 Lyra和OM1 Polaris，由PhenOMTM提供支持，PhenOMTM是一个用于个性化医疗和临床研究的人工智能驱动的数位表型平台。这些产品利用先进的预测和产生人工智慧平台以及深入的临床资料来增强医疗保健利害关係人的能力。

与医疗保健领域人工智慧整合相关的监管和道德挑战

由于人工智慧不断发展的性质，全球人工智慧驱动的医疗设备市场面临监管和道德挑战。 FDA 和 EMA 等监管机构已经建立了严格的流程来批准先进的人工智慧技术。然而，人工智慧的动态特性使得很难在静态标准下评估这些设备，从而导致产品开发的不确定性和潜在的延迟。对资料隐私和安全的道德担忧使情况更加复杂，因为人工智慧设备依赖大量患者资料，引发了对资料收集、储存和使用的担忧。人工智慧演算法中的偏见风险可能会导致不准确或不公平的结果。解决这些问题需要医疗保健提供者、技术开发商和政策制定者之间的合作，但在建立普遍接受的标准方面进展缓慢。

AI-powered medical devices are revolutionizing healthcare by utilizing AI technologies like machine learning, deep learning, and natural language processing to improve medical diagnosis, treatment, and patient monitoring. These devices analyze vast data, provide real-time insights, and automate complex tasks, enhancing efficiency and patient outcomes. From advanced imaging systems to wearable devices for continuous health monitoring, AI-powered medical devices are reshaping personalized and preventive care, optimizing hospital workflows, and driving a new era in medicine, enabling faster decision-making and more effective treatment strategies.

Market Dynamics: Drivers & Restraints

Increasing Demand For Personalized and Precision Medicine

The global AI-powered medical devices market is driven by the growing demand for personalized and precision medicine, which is revolutionizing patient care. Advancements in artificial intelligence technologies enable healthcare providers to analyze vast datasets, including genetic information, medical history, lifestyle factors, and real-time health metrics, to deliver highly customized treatment plans. AI algorithms integrated into wearable medical devices can monitor a patient's health parameters continuously, alert clinicians about potential issues before they become critical, and improve diagnostic accuracy in diagnostic imaging. These capabilities not only enhance patient outcomes but also optimize resource allocation by reducing unnecessary tests and hospitalizations.

As chronic diseases and aging populations rise globally, the need for precise and proactive care becomes increasingly critical. Healthcare policies and incentives in regions like North America and Europe encourage the adoption of AI-driven solutions. As the adoption of precision medicine grows, the integration of AI-powered medical devices into routine healthcare practices is expected to accelerate, driving market expansion significantly.

For instance, in May 2024, OM1 has launched three new products, OM1 Orion, OM1 Lyra, and OM1 Polaris, powered by PhenOMTM, an artificial intelligence-powered digital phenotyping platform for personalized medicine and clinical research. These products leverage advanced predictive and generative AI platforms and deep clinical data to empower healthcare stakeholders.

Regulatory and Ethical Challenges Associated with AI Integration in Healthcare

The global AI-powered medical devices market faces regulatory and ethical challenges due to the evolving nature of AI. Regulatory bodies like the FDA and EMA have established rigorous processes for approving advanced AI technologies. However, the dynamic nature of AI makes it difficult to evaluate these devices under static standards, leading to uncertainty and potential delays in product development. Ethical concerns around data privacy and security further complicate the situation, as AI-powered devices rely on vast amounts of patient data, raising concerns about data collection, storage, and usage. The risk of bias in AI algorithms can lead to inaccurate or inequitable outcomes. Collaboration between healthcare providers, technology developers, and policymakers is needed to address these issues, but progress in establishing universally accepted standards has been slow.

Segment Analysis

The global AI-powered medical devices market is segmented based on product type, technology application, end user and region.

Product type:

Hardware segment is expected to dominate the AI-powered medical devices market share

The hardware segment holds a major portion of the AI-powered medical devices market share and is expected to continue to hold a significant portion of the AI-powered medical devices market share during the forecast period.

The global AI-powered medical devices market relies heavily on hardware, including processors, sensors, and accelerators, for high-speed data processing and computational power. GPUs and TPUs are commonly used in AI-powered medical imaging devices for real-time image analysis and pattern recognition. Specialized sensors in wearable medical devices collect vital patient data, which AI systems analyze for actionable insights. Edge computing hardware integrates with these devices, allowing local data processing without cloud computing, ensuring faster responses and improved data security. The development of compact, energy-efficient hardware has made medical devices more portable and accessible for clinical and homecare settings. As AI-powered medical devices become more sophisticated, advancements in hardware technology will continue to drive their performance, scalability, and adoption across diverse healthcare applications.

For instance, in July 2024, Insilico has introduced PandaOmics Box, an AI-powered hardware platform for on-premise drug discovery and personalized medicine research. The platform aims to streamline the process of developing innovative medicines, which typically takes at least a decade and billions of dollars. Identifying effective targets and conducting biological analysis is a top priority in drug development.

Application:

Drug Discovery segment is the fastest-growing segment in AI-powered medical devices market share

The drug discovery segment is the fastest-growing segment in the AI-powered medical devices market share and is expected to hold the market share over the forecast period.

Drug discovery is a key driver in the AI-powered medical devices market, as it streamlines the traditional process of drug development. Advanced AI-powered devices can analyze large datasets, including genomic information, chemical compound libraries, and clinical trial results, to identify potential drug candidates more efficiently. These devices help researchers pinpoint molecular targets, predict drug efficacy, and identify side effects early in the development cycle, reducing the time required for new drugs to market. AI-driven systems also enable personalized medicine by integrating patient-specific data, allowing for drug design tailored to individual genetic profiles and disease conditions. This synergy between AI and drug development is increasingly recognized by pharmaceutical companies and healthcare providers, positioning drug discovery as a critical driver in the growth of the AI-powered medical devices market.

For instance, in December 2023, Merck has launched AIDDISON drug discovery software, the first software-as-a-service platform that integrates virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API). The platform combines generative AI, machine learning, and computer-aided drug-design to speed up drug development.

Geographical Analysis

North America is expected to hold a significant position in the AI-powered medical devices market share

North America holds a substantial position in the AI-powered medical devices market and is expected to hold most of the market share due to its robust healthcare infrastructure, advanced technologies, and supportive regulatory frameworks. Major players like Medtronic, GE Healthcare, and IBM Watson Health are leading the way in integrating AI into medical devices. The region's high adoption rate, research funding, and government initiatives like FDA's streamlined approval processes accelerate market growth. The increasing prevalence of chronic diseases and geriatric population also drive demand for AI-driven diagnostic and monitoring solutions.

For instance, in November 2024, Canon Medical USA is launching its latest AI-powered MRI system, the Vantage Galan 3T/Supreme Edition, at the Radiological Society of North America (RSNA) 2024 conference in Chicago. The system, which has been released in other territories, features no third-party components and a Japan-made magnet, providing an expanded field of view.

Moreover, in August 2024, The U.S. Department of Health and Human Services has allocated $1.5 Billion to the Advanced Research Projects Agency for Health (ARPA-H) to enhance the reliability and usability of artificial intelligence-enabled medical devices. The funding is part of the Performance and Reliability Evaluation for Continuous Modifications and Useability of Artificial Intelligence (PRECISE-AI) initiative, which aims to improve the use and maintenance of AI tools in clinical settings.

Europe is growing at the fastest pace in the AI-powered medical devices market

Europe holds the fastest pace in the AI-powered medical devices market and is expected to hold most of the market share due to its focus on innovation, research collaborations, and high healthcare quality standards. Countries like Germany, the UK, and France have invested heavily in AI research, particularly in medical imaging and robotics. The European Union's Horizon Europe program supports AI adoption through funding and partnerships. The aging population and increasing healthcare burden in Europe also drive demand for efficient diagnostic and therapeutic solutions. Regulatory advancements like the EU Medical Device Regulation promote innovation in AI-based solutions. Both public and private healthcare systems are incorporating AI to reduce costs and improve efficiency.

For instance, in October 2024, Olympus Europe has approved its cloud-AI endoscopy medical devices, CADDIE, CADU, and SMARTIBD, as CE-marked in Europe under the Medical Device Regulation (MDR). This marks a significant milestone in Olympus' efforts to improve clinical outcomes and operational efficiency in endoscopy. Olympus, a market leader in capital equipment for endoscopy, aims to enhance its hardware portfolio with cloud-based AI capabilities. The company's vision is to create an Intelligent Endoscopy Ecosystem that connects hardware, software, services, and data to address healthcare challenges, particularly in endoscopy.

Moreover, in December 2024, The Medicines and Healthcare products Regulatory Agency (MHRA) has chosen five AI-powered medical devices for its new AI Airlock pilot scheme. The initiative aims to streamline the regulation of AI-based medical technologies, ensuring quicker and safer access for NHS patients. The selected technologies include those for cancer, chronic respiratory disease, and radiology. The AI Airlock serves as a regulatory "sandbox," allowing manufacturers to test evidence collection strategies under MHRA guidance in a controlled virtual environment.

Competitive Landscape

The major global players in the AI-powered medical devices market include Stryker Corporation, Medtronic, GE Healthcare, Philips Healthcare, Siemens Healthineers, Johnson & Johnson, Micron Technology Inc, Nvidia Corporation, Caption Health, Augmedix, Inc among others.

Emerging Players

The emerging players in the AI-powered medical devices market include Zebra Medical Vision, Aidoc, Butterfly Network, HeartFlow, Viz.ai and among others.

Key Developments

In November 2024, GE HealthCare has launched an AI Innovation Lab to accelerate early-concept AI solutions. The lab is part of GE HealthCare's broader AI and digital strategy, which focuses on integrating AI into medical devices, building AI applications for decision-making, and using AI for better outcomes and operational efficiencies. The company's investment in cloud technology supports this strategy.
In November 2023, Meihua International Medical Technologies Co. (MHUA), a Chinese manufacturer and provider of disposable medical devices, launched Speed Fox, an AI-powered warehouse management and logistics platform. Developed in collaboration with a Chinese higher education institution, MHUA aims to diversify its business and revolutionize medical device logistics.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global AI-powered medical devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Demand for Personalized and Precision Medicine
- 4.1.2. Restraints
  - 4.1.2.1. Regulatory and Ethical Challenges Associated with AI Integration in Healthcare
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
- 6.1.2. Market Attractiveness Index, By Product type
6.2. Hardware*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Software
6.4. Services

7. By Technology

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
7.2. Machine Learning*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Deep Learning
7.4. Natural Language Processing (NLP)
7.5. Computer Vision
7.6. Predictive Analytics

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Virtual Nursing Assistants
8.4. Emergency Room & Surgery
8.5. Healthcare Assistance Robots
8.6. Medical Imaging & Diagnostics
8.7. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & Clinics*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Research Institutes
9.5. Ambulatory Surgical Centers (ASCs)
9.6. Homecare Settings

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Stryker Corporation*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Medtronic
12.3. GE Healthcare
12.4. Philips Healthcare
12.5. Siemens Healthineers
12.6. Johnson & Johnson
12.7. Micron Technology Inc
12.8. Nvidia Corporation
12.9. Caption Health
12.10. Augmedix, Inc

LIST NOT EXHAUSTIVE